Ginkgo Bioworks acquires gene therapy assets from StrideBio
E_Y_E
- Ginkgo Bioworks (NYSE:DNA) announced Wednesday the acquisition of capsid discovery and engineering platform assets related to adeno-associated virus (AAV) from gene therapy company StrideBio. AAV is a viral vector used in the development of gene therapies.
- With the transaction, Ginkgo (DNA) also gets access to StrideBio's existing library of capsids which will be available for licensing and partnerships.
- As part of the deal, Ginkgo (DNA) also acquires IP rights and data related to StrideBio's lead preclinical asset for the rare genetic disease arrhythmogenic right ventricular cardiomyopathy. The company expects to sell or out-license the asset to a commercial partner.
- One employee from StrideBio will join Ginkgo's (DNA) mammalian engineering team following the transaction.
- Read: Seeking Alpha contributor UFD Capital issued a Sell rating on Ginkgo (DNA) in February, noting concerns over its revenue growth and operating losses.